news
Trial finds lopinavir/ritonavir and Arbidol ineffective for mild-to-moderate COVID-19
A Phase IV trial in 86 patients with mild-to-moderate COVID-19 has indicated that lopinavir/ritonavir (LPV/r) and Arbidol do not improve clinical outcomes.
List view / Grid view
Influenza
news
Production of Avigan® Tablet (favipiravir) accelerated for use against COVID-19
FUJIFILM intends to accelerate production of Avigan to 100,000 treatment courses per month by July and up to 300,000 by September 2020 to meet demand for possible use treating COVID-19.
news
Clinical trials for COVID-19 treatments show mixed results, says study
Despite some positive results from clinical trials for COVID-19 treatments, separate tests of the same therapies have not met primary endpoints.
news
Committee for Medicinal Products for Human Use (CHMP) meeting highlights
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
news
High-density microarray patch could provide alternative to syringe vaccine delivery
A clinical trial has shown that delivery of vaccines via a new high-density microarray patch (HD-MAP) induces a better immune response than needles or syringes.
news
Report indicates seasonal influenza vaccine market in Asia will reach $1bn by 2028
A new report indicates that drug launches and new formulations will drive the growth of the seasonal influenza vaccine market in China, India and Japan from $914m in 2018 to $1.05bn in 2028.
news
Seasonal influenza vaccine market to be worth $6.5bn by 2028
The transition from egg-based towards cell-based, recombinant and universal influenza vaccines will drive growth in the seasonal influenza vaccine market, a report has said.
news
Single vaccination approach developed to combat respiratory diseases
Scientists have developed a single vaccination approach to simultaneously combat influenza and pneumococcal infections.
news
Further advances in cell-based influenza vaccine technology announced
An influenza vaccine manufacturer has announced it is filing an Annual Strain Update with the US Food and Drug Administration (FDA) in the coming weeks due to advances in influenza vaccine technology.
news
Flu’s response to Xofluza explored
Scientists are now investigating the Xofluza mode of action in detail and have uncovered possible mechanisms by which viral resistance to it could emerge...
news
Sponsored trial of a universal influenza vaccine begins
A Phase 2 clinical trial of an investigational universal influenza vaccine intended to protect against multiple strains of the virus has begun in the United States...
news
H7N9 influenza vaccine clinical trials begin
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States...
news
Strategic plan for developing a universal influenza vaccine unveiled
NIAID officials detail the Institute’s new strategic plan for addressing the research areas essential to creating a safe and effective universal influenza vaccine...
news
Nanoparticle vaccine offers universal protection against influenza
Researchers have developed a universal vaccine to combat influenza A viruses that produces long-lasting immunity...
news
4-in-1 vaccine may provide lifelong protection against influenza
A vaccine combining centralised ancestral genes from four major influenza strains appears to provide broad protection against influenza...
